Harvard Bioscience Announces Third Quarter 2021 Financial Results

November 3, 2021

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

Revenue up 23% year-over-year as sales momentum continues
Pre-clinical product revenue up 28%
Cellular and Molecular Technologies (CMT) product revenue up 19%

HOLLISTON, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the period ended September 30, 2021.

Jim Green, Chairman and CEO said, “The positive trends we reported in the first half of 2021 have carried through with our strong top line performance in Q3. Demand for our pre-clinical products was very strong, with revenue up 28% over prior year, and also up significantly over pre-Covid levels. Our CMT products also experienced meaningful growth, up 19% over prior year as academic lab sales continue to recover. Operating income was adversely impacted by increased material, freight and labor costs associated with ongoing global supply disruptions.”

Mr. Green concluded, “We expect revenue growth of 15% to 17% for 2021 compared to 2020 based on sales momentum, up from prior expectations of 12% to 15%. Although supply disruptions are forcing extra costs in the short term, we still expect adjusted operating margin expansion to the mid-teens for the year.”


Quarterly Financial Results Summary	Q3'21					Q3'20

Revenues		$	29.7		million		$	24.0		million

Operating Income (GAAP)		$	0.5		million		$	0.2		million
Adjusted Operating Income		$	3.9		million		$	3.6		million
Operating Margin (GAAP)			1.8		%			0.8		%
Adjusted Operating Margin			13.3		%			14.8		%

Loss Per Share (GAAP)		$	(0.00	)			$	(0.03	)
Adjusted Diluted Earnings Per Share		$	0.06				$	0.04

Net Debt*		$	40.9		million		$	41.6		million

* Debt outstanding less cash and cash equivalents

For more details on Q3 performance, a slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins.

Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, diluted earnings per share and adjusted EBITDA. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Webcast and Conference Call Details

Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 8391005.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, adjusted diluted earnings per share, and adjusted EBITDA. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), adjusted earnings (loss) per diluted share, and adjusted EBITDA are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company’s business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.


													Exhibit 1
HARVARD BIOSCIENCE, INC.
Consolidated Statements of Operations
(unaudited, in thousands, except per share data)

				Three Months Ended					Nine Months Ended
				September 30, 2021			September 30, 2020			September 30, 2021			September 30, 2020

	Revenues		$	29,663		$	24,037		$	85,849		$	71,116
	Cost of revenues			13,355			10,542			37,757			30,783
		Gross profit		16,308			13,495			48,092			40,333

	Operating expenses:
		Sales and marketing expenses		6,183			4,588			17,299			14,446
		General and administrative expenses		5,458			5,399			18,190			17,828
		Research and development expenses		2,660			1,949			7,848			6,336
		Amortization of intangible assets		1,459			1,377			4,388			4,258
	Total operating expenses			15,760			13,313			47,725			42,868

	Operating income			548			182			367			(2,535	)

	Other (expense) income:
		Interest expense		(373	)		(1,205	)		(1,161	)		(3,737	)
		Other expense, net		(130	)		(392	)		(477	)		(472	)
	Total other expense			(503	)		(1,597	)		(1,638	)		(4,209	)

	Income (loss) before income taxes			45			(1,415	)		(1,271	)		(6,744	)
	Income tax expense (benefit)			215			(317	)		(22	)		451
	Net loss		$	(170	)	$	(1,098	)	$	(1,249	)	$	(7,195	)

	Loss per common share:
		Basic and diluted	$	(0.00	)	$	(0.03	)	$	(0.03	)	$	(0.19	)

	Weighted-average common shares:
		Basic and diluted		40,754			38,920			40,202			38,540


					Exhibit 2
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheets
(unaudited, in thousands)

			September 30, 2021		December 31, 2020
	Assets
	Cash and cash equivalents	$	5,548	$	8,317
	Accounts receivables		18,340		17,766
	Inventories		25,978		22,262
	Other current assets		5,820		3,355
	Total current assets		55,686		51,700
	Property, plant and equipment		3,453		3,960
	Goodwill and other intangibles		86,928		91,741
	Other long-term assets		7,805		8,853
	Total assets	$	153,872	$	156,254

	Liabilities and Stockholders' Equity
	Current portion, long-term debt	$	2,470	$	1,721
	Other current liabilities		21,036		19,332
	Total current liabilities		23,506		21,053
	Long-term debt		42,740		46,286
	Other long-term liabilities		10,739		12,234
	Stockholders’ equity		76,887		76,681
	Total liabilities and stockholders’ equity	$	153,872	$	156,254


						Exhibit 3
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)

		Nine Months Ended
		September 30, 2021			September 30, 2020
	Cash flows from operating activities:
	Net loss	$	(1,249	)	$	(7,195	)
	Adjustments to operating cash flows		8,547			8,676
	Changes in operating assets and liabilities		(6,153	)		5,360
	Net cash provided by operating activities		1,145			6,841

	Cash flows from investing activities:
	Additions to property, plant and equipment		(837	)		(1,088	)
	Addition to intangible assets		(150	)		-
	Net cash used in investing activities		(987	)		(1,088	)

	Cash flows from financing activities:
	Proceeds from borrowings		2,500			9,615
	Repayments of debt		(5,500	)		(20,251	)
	Payments of debt issuance costs		(102	)		-
	Proceeds from exercise of stock options		2,909			194
	Taxes related to net share settlemenrt of equity awards		(2,653	)		(882	)
	Net cash used in financing activities		(2,846	)		(11,324	)

	Effect of exchange rate changes on cash		(81	)		42
	Decrease in cash and cash equivalents		(2,769	)		(5,529	)
	Cash and cash equivalents at the beginning of period		8,317			8,335
	Cash and cash equivalents at the end of period	$	5,548		$	2,806


																Exhibit 4
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended September 30, 2021
(in thousands, except per share data)

				Stock-Based			Acquired Assets			Restructuring,			Income
Statement of Operations	GAAP			Compensation			Amortization			Transformation			Taxes				ADJUSTED

Revenues	$	29,663			-			-			-			-			$	29,663
Cost of revenues		13,355			(32	)		(15	)		(94	)		-				13,214
Gross profit		16,308			32			15			94			-				16,449

Gross Margin		55.0	%															55.5	%

Operating expenses:
Sales and marketing expenses		6,183			(149	)		(2	)		(261	)		-				5,771
General and administrative expenses		5,458			(790	)		(16	)		(426	)		-				4,226
Research and development expenses		2,660			(33	)		(10	)		(113	)		-				2,504
Amortization of intangible assets		1,459			-			(1,459	)		-			-				-
Total operating expenses		15,760			(972	)		(1,487	)		(800	)		-				12,501

Operating Expenses - % of Revenue		53.1	%															42.1	%

Operating income		548			1,004			1,502			894			-				3,948

Operating Margin		1.8	%															13.3	%

Other (expense) income:
Interest expense		(373	)		-			-			-			-				(373	)
Other expense, net		(130	)		-			-			-			-				(130	)
Total other expense		(503	)		-			-			-			-				(503	)

Income before income taxes		45			1,004			1,502			894			-				3,445
Income tax expense		215			-			-			-			580				795
Net (loss) income	$	(170	)	$	1,004		$	1,502		$	894		$	(580	)		$	2,650

(Loss) income per share	$	(0.00	)														$	0.06

Diluted weighted average common shares		40,754																43,500


																Exhibit 4.1
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended September 30, 2020
(in thousands, except per share data)

				Stock-Based			Acquired Assets			Restructuring,			Income
Statement of Operations	GAAP			Compensation			Amortization			Transformation			Taxes				ADJUSTED

Revenues	$	24,037			-			-			-			-			$	24,037
Cost of revenues		10,542			(18	)		(19	)		(19	)		-				10,486
Gross profit		13,495			18			19			19			-				13,551

Gross Margin		56.1	%															56.4	%

Operating expenses:
Sales and marketing expenses		4,588			(91	)		(2	)		(15	)		-				4,480
General and administrative expenses		5,399			(908	)		(18	)		(834	)		-				3,639
Research and development expenses		1,949			(62	)		(13	)		(9	)		-				1,865
Amortization of intangible assets		1,377			-			(1,377	)		-			-				-
Total operating expenses		13,313			(1,061	)		(1,410	)		(858	)		-				9,984

Operating Expenses - % of Revenue		55.4	%															41.5	%

Operating income		182			1,079			1,429			877			-				3,567

Operating Margin		0.8	%															14.8	%

Other (expense) income:
Interest expense		(1,205	)		-			-			-			-				(1,205	)
Other expense, net		(392	)		-			-			-			-				(392	)
Total other expense		(1,597	)		-			-			-			-				(1,597	)

(Loss) income before income taxes		(1,415	)		1,079			1,429			877			-				1,970
Income tax (benefit) expense		(317	)		-			-			-			823				506
Net (loss) income	$	(1,098	)	$	1,079		$	1,429		$	877		$	(823	)		$	1,464

(Loss) income per share	$	(0.03	)														$	0.04

Diluted weighted average common shares		38,920																40,307


																Exhibit 4.2
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Nine Months Ended September 30, 2021
(in thousands, except per share data)

				Stock-Based			Acquired Assets			Restructuring,			Income
Statement of Operations	GAAP			Compensation			Amortization			Transformation			Taxes				ADJUSTED

Revenues	$	85,849			-			-			-			-			$	85,849
Cost of revenues		37,757			(83	)		(51	)		(247	)		-				37,376
Gross profit		48,092			83			51			247			-				48,473

Gross Margin		56.0	%															56.5	%

Operating expenses:
Sales and marketing expenses		17,299			(373	)		(6	)		(375	)		-				16,545
General and administrative expenses		18,190			(2,593	)		(49	)		(2,380	)		-				13,168
Research and development expenses		7,848			(87	)		(32	)		(408	)		-				7,321
Amortization of intangible assets		4,388			-			(4,388	)		-			-				-
Total operating expenses		47,725			(3,053	)		(4,475	)		(3,163	)		-				37,034

Operating Expenses - % of Revenue		55.6	%															43.1	%

Operating (loss) income		367			3,136			4,526			3,410			-				11,439

Operating Margin		0.4	%															13.3	%

Other (expense) income:
Interest expense		(1,161	)		-			-			-			-				(1,161	)
Other expense, net		(477	)		-			-			-			-				(477	)
Total other expense		(1,638	)		-			-			-			-				(1,638	)

(Loss) income before income taxes		(1,271	)		3,136			4,526			3,410			-				9,801
Income tax (benefit) expense		(22	)		-			-			-			2,365				2,343
Net (loss) income	$	(1,249	)	$	3,136		$	4,526		$	3,410		$	(2,365	)		$	7,458

(Loss) income per share	$	(0.03	)														$	0.17

Diluted weighted average common shares		40,202																43,113


																Exhibit 4.3
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Nine Months Ended September 30, 2020
(in thousands, except per share data)

				Stock-Based			Acquired Assets			Restructuring,			Income
Statement of Operations	GAAP			Compensation			Amortization			Transformation			Taxes				ADJUSTED

Revenues	$	71,116			-			-			-			-			$	71,116
Cost of revenues		30,783			(43	)		(59	)		(21	)		-				30,660
Gross profit		40,333			43			59			21			-				40,456

Gross Margin		56.7	%															56.9	%

Operating expenses:
Sales and marketing expenses		14,446			(205	)		(6	)		(125	)		-				14,110
General and administrative expenses		17,828			(2,248	)		(52	)		(3,480	)		-				12,048
Research and development expenses		6,336			(145	)		(44	)		(7	)		-				6,140
Amortization of intangible assets		4,258			-			(4,258	)		-			-				-
Total operating expenses		42,868			(2,598	)		(4,360	)		(3,612	)		-				32,298

Operating Expenses - % of Revenue		60.3	%															45.4	%

Operating (loss) income		(2,535	)		2,641			4,419			3,633			-				8,158

Operating Margin		-3.6	%															11.5	%

Other (expense) income:
Interest expense		(3,737	)		-			-			-			-				(3,737	)
Other expense, net		(472	)		-			-			-			-				(472	)
Total other expense		(4,209	)		-			-			-			-				(4,209	)

(Loss) income before income taxes		(6,744	)		2,641			4,419			3,633			-				3,949
Income tax expense		451			-			-			-			435				886
Net (loss) income	$	(7,195	)	$	2,641		$	4,419		$	3,633		$	(435	)		$	3,063

(Loss) income per share	$	(0.19	)														$	0.08

Diluted weighted average common shares		38,540																39,824


									Exhibit 5
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
(in thousands)
		Three Months Ended				Nine Months Ended
		September 30, 2021		September 30, 2020		September 30, 2021		September 30, 2020
	Operating income	$	548	$	182	$	367	$	(2,535	)
	Amortization of intangible assets		1,459		1,377		4,388		4,258
	Depreciation expense		420		471		1,311		1,453
	Stock-based compensation expense		1,004		1,079		3,136		2,641
	Restructuring and transformation costs		893		877		3,408		3,635
	Adjusted EBITDA	$	4,324	$	3,986	$	12,610	$	9,452

Press Release

Harvard Bioscience Announces Third Quarter 2021 Financial Results